ArticleJapanese journal of ophthalmology2024
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration.
Article in Japanese journal of ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- [Real-world experience with aflibercept 8 mg for treatment of neovascular age-related macular degeneration after 12 months].Die Ophthalmologie · 2026Article
- Migration of perivenous opacities during retinal vasculopathy and retinal vasculitis.American journal of ophthalmology case reports · 2026Article
- Six-month outcomes with a reduced two-injection induction (2+TAE) regimen of aflibercept 8 mg in treatment-naive neovascular age-related macular degeneration.Japanese journal of ophthalmology · 2026Article
- Aflibercept 8mg for neovascular age related macular degeneration refractory to faricimab.Japanese journal of ophthalmology · 2026Article
- One-year outcomes of treat-and-extend regimen with intravitreal aflibercept 8 mg for treatment-naïve neovascular age-related macular degeneration.Japanese journal of ophthalmology · 2026Article
- Comparison of adverse renal events between ranibizumab and aflibercept in patients with diabetic macular oedema: A global network study.Eye (London, England) · 2026Article
- Real-World Outcomes of Switching to Aflibercept 8 mg in Previously Treated Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Comparison of Choroidal Morphological Changes Between Aflibercept 8 mg and Faricimab-svoa in Treatment-Naïve Polypoidal Choroidal Vasculopathy and Pachychoroid Neovasculopathy.Journal of clinical medicine · 2026Article
- Early real-world outcomes of aflibercept 8 mg in previously treated neovascular age-related macular degeneration.Eye (London, England) · 2026Article
- OCCLUSIVE RETINAL VASCULITIS AFTER AFLIBERCEPT 8 mg INJECTION FOR WET MACULAR DEGENERATION.Retinal cases & brief reports · 2026Article
- Real-world six-month outcomes after switching from aflibercept 2 mg to aflibercept 8 mg for neovascular age-related macular degeneration.Japanese journal of ophthalmology · 2026Observational
- Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration.Acta ophthalmologica · 2026Article
- Lower Rates of Intraocular Inflammation with Aflibercept 8 mg Delivered via Pre-Filled Syringe Versus Vial.Ophthalmology and therapy · 2026Article
- Aflibercept 8 mg in Neovascular AMD-A Fast-Drying Anti-VEGF Drug: A Prospective Morpho-Functional Pilot Study.Ophthalmology and therapy · 2026Article
- Systemic and ocular complications related to intravitreal administration of anti-VEGF agents.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
- Incidence and Clinical Course of Intraocular Inflammation Following Pharmacy-Compounded Intravitreal Aflibercept 8mg for Neovascular AMD: A Real-World Cohort Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Treatment outcomes of switching to aflibercept 8 mg in previously-treated neovascular age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Intraocular inflammation following aflibercept 8 mg: real-world data from a multicentre retrospective observational study.International journal of retina and vitreous · 2025Article
- Bilateral Sterile Intraocular Inflammation Following Intravitreal Aflibercept 8 mg Injections: A Case Report.Reports (MDPI) · 2025Article
- Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate short-term outcomes of intravitreal injection of aflibercept 8 mg for neovascular age-related macular degeneration (nAMD). STUDY
designRetrospective, interventional case series.
methodsWe retrospectively studied 35 eyes of 34 consecutive patients with nAMD, assessing best-corrected visual acuity (BCVA), foveal thickness (FT), and central choroidal thickness (CCT) before and 4 weeks after the initial intravitreal dose of aflibercept 8 mg. The rate of achieving a dry macula and the incidence of intraocular inflammation (IOI) at week 4 were also determined.
resultsBCVA showed significant improvement, with significant reductions in FT and CCT 4 weeks after the initial injection of aflibercept 8 mg (all P < 0.01), with a dry macula being achieved in 20 eyes (57.1%). However, 3 eyes (8.6%) developed non-infectious IOI associated with retinal vasculitis, an adverse event not reported previously. The IOI in these eyes was relatively mild and treated with a posterior subtenon injection of triamcinolone acetonide with or without betamethasone eye drops, resulting in amelioration of IOI without any visual loss.
conclusionsIntravitreal aflibercept 8 mg appears to be effective for improving visual acuity and ameliorating exudative changes in eyes with nAMD. However, special attention should be given to the potential development of IOI associated with retinal vasculitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.